The AMR Centre (AMRC) has today announced a multi-year co-development agreement with Massachusetts-based clinical stage biopharmaceutical company Microbiotix, Inc. to progress a novel treatment to tackle the bacterium that is responsible for gonorrhoea.
18 March, 2020